Results 11 to 20 of about 199,032 (289)
Brazilian Journal of Oncology, 2022 Objectives: To report real-world data of a cohort of patients treated with immune-checkpoint inhibitors in Brazil, with focus in immune-related adverse events.
Maria Paula Furtado Santos +9 more
doaj +2 more sources
Cardiotoxicity of immune checkpoint inhibitors
ESMO Open, 2017 Cardiac toxicity after conventional antineoplastic drugs (eg, anthracyclines) has historically been a relevant issue. In addition, targeted therapies and biological molecules can also induce cardiotoxicity. Immune checkpoint inhibitors are a novel class of anticancer drugs, distinct from targeted or tumour type-specific therapies.
VARRICCHI, GILDA +7 more
openaire +4 more sources
Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy
Vaccines, 2023 Hepatitis B virus (HBV) infection is the main risk factor for the development of hepatocellular carcinoma (HCC), the most common type of liver cancer, with high incidence and mortality worldwide.
Jin Zhang +5 more
doaj +2 more sources
Frontiers in Oncology, 2022 Hepatocellular carcinoma is one of the leading causes of cancer mortality globally, and its incidence is increasing. Immune checkpoint therapy has revolutionized the treatment of hepatocellular carcinoma over the past few years.
Qingqing Xie +4 more
doaj +1 more source
Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option?
Frontiers in Immunology, 2022 Immune checkpoint inhibitor (ICI) is one of the most important tumor treatment methods. Although the therapeutic efficiency of immune checkpoint inhibitor mono-therapy is limited, the combination of chemotherapy plus immune checkpoint inhibitors has ...
Xinye Qian +5 more
doaj +1 more source
Immune Checkpoint Inhibitors [PDF]
JAMA Oncology, 2015 Undoubtedly the discovery of immune checkpoints such as CTLA-4 and PD-1 has been crucial to the development of cancer immunotherapy. Although these molecules were originally discovered as molecules playing a role in T cell activation or apoptosis, subsequent preclinical research showed their important role in the maintenance of peripheral immune ...
John B A G, Haanen, Caroline, Robert
openaire +3 more sources
Immune checkpoint inhibitors in malignancy [PDF]
Australian Prescriber, 2019 Immune checkpoints normally stop the body from mounting an immune response against healthy cells. Some cancers can acquire these checkpoints so that the tumour cells are not recognised by the immune systemInhibiting the checkpoints therefore enables the tumour cells to be recognised and allows an immune response to be activated against themImmune ...
Luke, Ardolino, Anthony, Joshua
openaire +2 more sources
Immune Checkpoint Inhibitors and Neurotoxicity
Current Neuropharmacology, 2021 : Immune checkpoint inhibitors (ICIs) have recently been used as a promising treatment for cancer, while their toxicity and immune-related side effects can be seen in any organ, including the nervous system. In contrast to other immune-related adverse events (irAEs), neurological irAEs (nAEs) are rare, with varying incidence and symptom complexity ...
Zhao, Zhiyi +4 more
openaire +3 more sources
Zhongliu Fangzhi Yanjiu, 2020 In recent years, immunotherapy has been continuously developed, and the safety and efficacy of immune checkpoint inhibitors combined with intracranial radiotherapy for melanoma brain metastasis have been initially recognized.
HE Qian, REN Qinglan
doaj +1 more source
Risk of diabetes mellitus among users of immune checkpoint inhibitors: A population‐based cohort study [PDF]
, 2023 Background Immune checkpoint inhibitors (ICIs) are increasingly established cancer therapeutics, but they are associated with new-onset diabetes mellitus (DM).
Kong, Dicken +11 more
core +1 more source